Ropinirole as an effective adjunctive treatment for clozapine-resistant negative symptoms in simple schizophrenia: A case report

Journal of Clinical Psychopharmacology

Volumn 32, Issue 5, 2012, Pages 719-720

  Michalopoulou, Panayiota G ^a   Azim, Adnan ^a   Tracy, Derek ^a   Shergill, Sukhwinder S ^a  

^a Section on Schizophrenia Imaging and Therapeutics   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; MIRTAZAPINE; OLANZAPINE; RISPERIDONE; ROPINIROLE;

ABSENCE OF SIDE EFFECTS; ADULT; CASE REPORT; DRUG DOSE TITRATION; DRUG EFFICACY; DSM-IV; HOSPITAL ADMISSION; HUMAN; INTELLIGENCE QUOTIENT; LETTER; MALE; MEMORY; MENTAL HEALTH SERVICE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL WITHDRAWAL; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; HUMANS; INDOLES; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84865865347     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318267062c     Document Type: Letter

References (18)

1. Black DW, Boffeli TJ. Simple schizophrenia: revisited. Compr Psychiatry. 1990;31: 344-349.
2. Kirkpatrick B, Fenton WS, Carpenter WT, et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
3. Czernecki V, Schupbach M, Yaici S, et al. Apathy following subthalamic stimulation in Parkinson disease: a dopamine responsive symptom. Mov Disord. 2008;23:964-969.
4. Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. Arch Gen Psychiatry. 1982;39:784-788.
5. Marin RS. Apathy: a neuropsychiatric syndrome. J Neuropsychiatry Clin Neurosci. 1991;3:243-254.
6. Jost WH, Angersbach D. Ropinirole, a non-ergoline dopamine agonist. CNS Drug Rev. 2005;11:253-272.
7. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 StudyGroup. Neurology. 1999;53:364-370.
8. Weinberger DR, Lipska BK. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr Res. 1995;16:87-110.
9. Juckel G, Schlagenhauf F, Koslowski M, et al. Dysfunction of ventral striatal reward prediction in schizophrenic patients treated with typical, not atypical, neuroleptics. Psychopharmacology. 2006;187:222-228.
10. Buchanan RW, Breier A, Kirkpatrick B, et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155:751-760.
11. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159: 255-262.
12. Ozdemir V, Kalow W, Okey AB, et al. Treatment-resistance to clozapine in association with ultrarapid CYP1A2 activity and the CY9A polymorphism in intron 1 of the CYP1A2 gene: effect of grapefruit juice and low-dose fluvoxamine. J Clin Psychopharmacol. 2001;21: 603-607.
13. Nielsen J, Damkier P, Lublin H, et al. Optimizing clozapine treatment. Acta Psychiatr Scand. 2011;123:411-422.
14. Sernyak MJ, Rosenheck R, Desai R, et al. Impact of clozapine prescription on inpatient resource utilization. J Nerv Ment Dis. 2001;189:766-773.
15. Buckley P, Miller A, Olsen J, et al. When symptoms persist: clozapine augmentation strategies. Schizophr Bull. 2001;27:615-628.
16. Bloomer JC, Clarke SE, Chenery RJ. In vitro identification of the P450 enzymes responsible for the metabolism of ropinirole. Drug Metab Dispos. 1997;25: 840-844.
17. Thalamas C, Taylor A, Brefel-Courbon C, et al. Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease. Eur J Clin Pharmaco. 1999;55:299-303.
18. Joffe G, Terevnikov V, Joffe M, et al. Add-on mirtazapine enhances antipsychotic effect of first generation antipsychotics in schizophrenia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2009;108:245-251.